It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hypoxia is a common feature in tumors and induces signaling that promotes tumor cell survival, invasion, and metastasis, but the impact of hypoxia inducible factor (HIF) signaling in the primary tumor on dissemination to bone in particular remains unclear. To better understand the contributions of hypoxia inducible factor 1 alpha (HIF1α), HIF2α, and general HIF pathway activation in metastasis, we employ a PyMT-driven spontaneous murine mammary carcinoma model with mammary specific deletion of Hif1α, Hif2α, or von Hippel-Lindau factor (Vhl) using the Cre-lox system. Here we show that Hif1α or Hif2α deletion in the primary tumor decreases metastatic tumor burden in the bone marrow, while Vhl deletion increases bone tumor burden, as hypothesized. Unexpectedly, Hif1α deletion increases metastatic tumor burden in the lung, while deletion of Hif2α or Vhl does not affect pulmonary metastasis. Mice with Hif1α deleted tumors also exhibit reduced bone volume as measured by micro computed tomography, suggesting that disruption of the osteogenic niche may be involved in the preference for lung dissemination observed in this group. Thus, we reveal that HIF signaling in breast tumors controls tumor dissemination in a site-specific manner.
Todd et al employ a PyMT-driven spontaneous murine mammary carcinoma model with mammary-specific deletion of hypoxia inducible factors Hif1α, Hif2α, or von Hippel-Lindau factor to further investigate their role in bone and lung metastasis. They find that HIF signaling in breast tumours controls tumour dissemination in a site-specific manner, which could inform the development of therapies targeting metastasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Vanderbilt University, Graduate Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University, Vanderbilt Center for Bone Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
2 Vanderbilt University, Vanderbilt Center for Bone Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
3 National Cancer Institute, National Institutes of Health, Tumor Microenvironment and Metastasis Section, Pediatric Oncology Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
4 Vanderbilt University, Vanderbilt Center for Bone Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University, Department of Medicine, Health, and Society, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
5 Vanderbilt University, Department of Molecular Physiology and Biophysics, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
6 Vanderbilt University Medical Center, Department of Pathology, Microbiology and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
7 Vanderbilt University, Vanderbilt Center for Bone Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University, Department of Chemical and Biomolecular Engineering, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
8 Vanderbilt University, Graduate Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University, Vanderbilt Center for Bone Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)